Lexaria Bioscience (LEXX)
(Delayed Data from NSDQ)
$3.13 USD
-0.18 (-5.44%)
Updated Aug 9, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Lexaria Bioscience Corp falls in the month of August .
All items in Millions except EPS data.
8/31/23 | 8/31/22 | 8/31/21 | 8/31/20 | 8/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 7 | 8 | 6 | 3 | 3 |
Income After Depreciation & Amortization | -7 | -7 | -6 | -3 | -3 |
Non-Operating Income | 0 | 0 | 2 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -7 | -7 | -4 | -4 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -7 | -7 | -4 | -4 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -7 | -7 | -4 | -4 | -4 |
Depreciation Footnote | 8/31/23 | 8/31/22 | 8/31/21 | 8/31/20 | 8/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -7 | -6 | -3 | -3 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -7 | -7 | -6 | -3 | -3 |
Earnings Per Share Data | 8/31/23 | 8/31/22 | 8/31/21 | 8/31/20 | 8/31/19 |
---|---|---|---|---|---|
Average Shares | 6.61 | 5.89 | 4.39 | 2.77 | NA |
Diluted EPS Before Non-Recurring Items | -1.01 | -1.24 | -0.95 | -1.50 | NA |
Diluted Net EPS (GAAP) | -1.01 | -1.24 | -0.95 | -1.50 | -1.50 |
Fiscal Year end for Lexaria Bioscience Corp falls in the month of August .
All items in Millions except EPS data.
5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | |
---|---|---|---|---|---|
Sales | 0.08 | 0.15 | 0.15 | 0.00 | 0.09 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Gross Profit | 0.08 | 0.15 | 0.15 | 0.00 | 0.08 |
SG&A, R&D, and Dept/Amort Expenses | 1.82 | 0.82 | 1.28 | 1.07 | 2.46 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.74 | -0.67 | -1.13 | -1.07 | -2.38 |
Non-Operating Income | -0.04 | 0.02 | -0.05 | -0.18 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.78 | -0.65 | -1.19 | -1.25 | -2.38 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.78 | -0.65 | -1.19 | -1.25 | -2.38 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.78 | -0.65 | -1.18 | -1.24 | -2.37 |
Earnings Per Share Data | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 |
---|---|---|---|---|---|
Average Shares | 13.86 | 10.77 | 9.05 | 6.61 | 6.44 |
Diluted EPS Before Non-Recurring Items | -0.13 | -0.06 | -0.13 | -0.12 | -0.37 |
Diluted Net EPS (GAAP) | -0.13 | -0.06 | -0.13 | -0.12 | -0.37 |